Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · Real-Time Price · USD
2.360
-0.010 (-0.42%)
Oct 28, 2025, 4:00 PM EDT - Market closed
Oramed Pharmaceuticals Revenue
Oramed Pharmaceuticals had revenue of $2.00M in the twelve months ending June 30, 2025.
Revenue (ttm)
$2.00M
Revenue Growth
n/a
P/S Ratio
48.53
Revenue / Employee
$500,000
Employees
4
Market Cap
96.77M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.34M | -1.36M | -50.43% |
| Dec 31, 2022 | 2.70M | -9.00K | -0.33% |
| Dec 31, 2021 | 2.71M | 9.00K | 0.33% |
| Aug 31, 2021 | 2.70M | -9.00K | -0.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ORMP News
- 6 days ago - Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives - PRNewsWire
- 6 months ago - Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals - GlobeNewsWire
- 6 months ago - Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical - PRNewsWire
- 8 months ago - Oramed Pharmaceuticals Issues Letter to Shareholders - PRNewsWire
- 9 months ago - Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin - PRNewsWire
- 1 year ago - Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt - PRNewsWire
- 1 year ago - Oramed Letter to Shareholders - PRNewsWire
- 1 year ago - Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock - PRNewsWire